Janice C. Parker
Department of Cardiovascular and Metabolic Diseases
Pfizer Inc.
Groton
Connecticut 06340
USA
Name/email consistency: high
- Preclinical studies and clinical trials for diabetes-second annual forum: identifying emerging therapies and improve trial efficiency. Parker, J. IDrugs (2004)
- Synergistic effect on insulin secretion from INS-1 cells of a sulfonylurea and a phosphodiesterase 3 inhibitor. Parker, J.C., VanVolkenburg, M.A., Gao, F. Life Sci. (2004)
- Glycemic control in mice with targeted disruption of the glucagon receptor gene. Parker, J.C., Andrews, K.M., Allen, M.R., Stock, J.L., McNeish, J.D. Biochem. Biophys. Res. Commun. (2002)
- Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. Parker, J.C. Adv. Drug Deliv. Rev. (2002)
- Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Parker, J.C., McPherson, R.K., Andrews, K.M., Levy, C.B., Dubins, J.S., Chin, J.E., Perry, P.V., Hulin, B., Perry, D.A., Inagaki, T., Dekker, K.A., Tachikawa, K., Sugie, Y., Treadway, J.L. Diabetes (2000)
- Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Parker, J.C., VanVolkenburg, M.A., Levy, C.B., Martin, W.H., Burk, S.H., Kwon, Y., Giragossian, C., Gant, T.G., Carpino, P.A., McPherson, R.K., Vestergaard, P., Treadway, J.L. Diabetes (1998)
- Structure-function analysis of a series of glucagon-like peptide-1 analogs. Parker, J.C., Andrews, K.M., Rescek, D.M., Massefski, W., Andrews, G.C., Contillo, L.G., Stevenson, R.W., Singleton, D.H., Suleske, R.T. J. Pept. Res. (1998)
- Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III. Parker, J.C., VanVolkenburg, M.A., Nardone, N.A., Hargrove, D.M., Andrews, K.M. Biochem. Biophys. Res. Commun. (1997)